My laboratory is currently interested in defining the mechanisms by which immune checkpoint proteins regulate anti-tumor immune responses and to develop rational therapeutics for cancer immunotherapy.
Specifically, we focus on delineating the mechanisms by which a novel immune checkpoint protein, V-domain Immunoglobulin Suppression of T cell Activation (VISTA), modulates immune responses to tumors. My research group has published a series of original research and review articles that address the inhibitory roles of VISTA during the development of anti-tumor immunity, autoimmunity, and inflammatory diseases (1-9). We have shown that VISTA is a critical immune checkpoint protein that controls myeloid cell- and T cell-mediated anti-tumor immunity, therefore is a valuable target for cancer immunotherapy.
Currently, we are committed to discovering novel inhibitory receptors that interact with VISTA and developing effective approaches that block VISTA-mediated immune checkpoint pathway and improve the efficacy of cancer immunotherapy.
Associate Staff, Translational Hematology and Oncology Research, Cleveland Clinic